Skip to content
value.today

Gilead Sciences, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2024–FY2025 (cash from operations less capital spending), from the statements below.

%

No three-year revenue growth on file: 5% to start with.

%

US Treasury 10-year yield on Nov 20, 2026: 4.92% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt or cash not on file: 0 to start with.

What today's price assumes

A market value of $193.5 B means free cash flow growing 7.3% a year for 10 years, then 2.5% for ever, at a 9.92% discount rate.

Cash-flow value of the shares
$163.8 B
-15% against the market value
Value of the whole business
$163.8 B
before net debt
Value from after year 10
53%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →0%2.5%5%7.5%10%
7.92%-21%-3%+17%+43%+74%
8.92%-32%-18%-2%+19%+44%
9.92%-41%-29%-15%+2%+22%
10.92%-48%-38%-26%-11%+6%
11.92%-53%-44%-34%-22%-7%

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

Cash-flow value$0 M$52.3 B$104.5 B$156.8 B$209.0 BMarket value $193.5 B

Your own DCF model

A full discounted-cash-flow model of Gilead Sciences, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against its own history

Gilead Sciences, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

18.6×

Now below its median of 21.9×, in the bottom quarter of its range; range 13.6× to 958.9× over 28 months.

0×240×479×719×959×2020202120222023202420252026P/E 19×Median 22×

Price to sales

6.3×

Now above its median of 4.9×, in the top quarter of its range; range 3.3× to 6.4× over 30 months.

0×2×3×5×6×2020202120222023202420252026Price to sales 6×Median 5×

Price to book

8.5×

Now above its median of 7.1×, in the top quarter of its range; range 3.2× to 9.7× over 30 months.

0×2×5×7×10×2020202120222023202420252026Price to book 9×Median 7×

As of Oct 26, 2026

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2026——————Wikidata
FY2025to Dec 31, 2025$29.4 B$8.5 B$10.0 B$563 M$9.5 B$17.4 BSEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$28.8 B$480 M$10.8 B$523 M$10.3 B$16.7 BSEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$27.1 B$5.7 B$8.0 B$585 M$7.4 B$18.9 BSEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$27.3 B$4.6 B$9.1 B$728 M$8.3 B$19.8 BSEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$27.3 B$6.2 B$11.4 B$579 M$10.8 B$21.4 BSEC annual report (10-K, 20-F)